416
R. Di Santo et al. / Il Farmaco 60 (2005) 409–417
[8] S. Maignan, J.-P. Guilloteau, Q. Zhou-Liu, C. Clément-Mella,
V. Mikol, Crystal structure of the catalytic domain of HIV-1 integrase
free and complexed with its metal cofactor: high level of similarity of
the active site with other viral integrases, J. Mol. Biol. 282 (1998)
359–368.
[9] Y. Goldur, R. Craigie, G.H. Cohen, T. Fujiwara, T. Yoshinaga,
T. Fujishita, H. Sugimoto, T. Endo, H. Murai, D.R. Davies, Structure
of the HIV-1 integrase catalytic domain complexed with an inhibitor:
a platform for antiviral drug design, Proc. Natl. Acad. Sci. USA 96
(1999) 13040–13043.
[10] F.D. Bushman, T. Fujiwara, R. Craigie, Retroviral DNA integration
directed by HIV integration protein in vitro, Science 249 (1990)
1555–1558.
[11] M.R. Fesen, K.W. Kohn, F. Leteurtre, Y. Pommier, Inhibitors of
human immunodeficiency virus integrase, Proc. Natl. Acad. Sci. USA
90 (1993) 2399–2403.
[12] M.R. Fesen, Y. Pommier, F. Leteurtre, S. Hiroguchi, J. Yung,
K.W. Kohn, Inhibition of HIV-1 integrase by flavones, caffeic acid
phenethyl ester (CAPE) and relaated compounds, Biochem. Pharma-
col. 48 (1994) 595–608.
Fig. 10. The RDS derivatives docked into the IN catalytic core. In purple is
also reported the IN. Hydrogen atom are omitted for sake of clarity.
[13] Z. Lin, N. Neamati, H. Zhao, Y. Kiryu, J.A. Turpin, C. Aberham,
K. Strebel, K. Kohn, M. Witvrouw, C. Pannecouque, Z. Debyser,
E. De Clercq, W.G. Rice, Y. Pommier, T.R. Burke Jr., Chicoric acid
analogues as HIV-1 integrase inhibitors, J. Med. Chem. 42 (1999)
1401–1414.
[14] W.E. Robinson Jr., M.G. Reinecke, S. Abdel-Malek, Q. Jia,
S.A. Chow, Inhibitors of HIV-1 replication that inhibit HIV integrase,
Proc. Natl. Acad. Sci. USA 93 (1996) 6326–6331.
[15] B. McDougall, P.J. King, B.W. Wu, Z. Hostomsky, M.G. Reinecke,
W.E. Robinson Jr., Dicaffeoylquinic and dicaffeoyltartaric acids are
selective inhibitors of human immunodeficiency virus type 1 inte-
grase, Antimicrob. Agents Chemother. 42 (1998) 140–146.
[16] N. Neamati, S. Sunder, Y. Pommier, Design and discovery of HIV-
1 integrase inhibitors, Drugs Discov. Today 2 (1997) 487–498.
Fig. 11. PLS coefficient plot of the preliminary 3D QSAR model. Derivative
[17] H. Hong, N. Neamati, H.E. Winslow, J.L. Christensen,A. Orr,Y. Pom-
mier, G.W.A. Milne, Identification of HIV-1 integrase inhibitors based
on a four-point pharmacophore, Antiviral Chem. Chemother. 9 (1998)
461–472.
RDS 1764 is also reported for interpretation. The IN is also reported for
polyhedron matching.
References
[18] M. Artico, R. Di Santo, R. Costi, E. Novellino, G. Greco, S. Massa,
E. Tramontano, M.E. Marongiu, A. De Montis, P. La Colla, Geometri-
cally and conformationally restrained cinnamoyl compounds as
inhibitors of HIV-1 integrase: synthesis, biological evaluation, and
molecular modeling, J. Med. Chem. 41 (1998) 3948–3960.
[1] M. Artico, Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors
(NNRTIs): a chemical survey from lead compounds to selected drugs
for clinical trials, Farmaco 51 (1996) 305–331.
[2] J.A. Martin, S. Redshaw, G.J. Thomas, Inhibitors of HIV proteinase,
Prog. Med. Chem. 32 (1995) 239–287.
[3] J.M. Kilby, S. Hopkins, T.M. Venetta, B. Dimassimo, G.A. Cloud,
J.Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Mat-
thews, M.R. Johnson, M.A. Nowak, G.M. Shaw, M.S. Saag, Potent
suppression of HIV-1 replication in humans by T-20, a peptide inhibi-
tor of gp41-mediated virus entry, Nat. Med. 4 (1998) 1302–1307.
[4] J. Stefenson, The art of ‘HAART’: researchers probe the potential and
limits of aggressive HIV treatments, J. Am. Med. Assoc. 277 (1997)
614–616.
[5] J. d’Angelo, J.F. Mouscadet, D. Desmaele, F. Zouhiri, H. Leh, HIV-
1 integrase: the next target for AIDS therapy? Pathol. Biol. 49 (2001)
237–246.
[6] R.L. La Femina, C.L. Schneider, H.L. Robbins, P.L. Callahan,
K. LeGrow, E. Roth, W.A. Schleif, E.A. Emini, Requirement of active
human immunodeficiency virus type 1 integrase enzyme for produc-
tive infection of human T-lymphoid cells, J. Virol. 66 (1992) 7414–
7419.
[19] C. Stanwell, B. Ye, S.H. Yuspa, T.R. Burke Jr., Cell protein cross-
linking by erbstatin and related compounds, Biochem. Pharmacol. 52
(1996) 475–480.
[20] F. Zouhiri, J.-F. Mouscardet, K. Mekouar, D. Desmaële, D. Savouré,
H. Leh, F. Subra, M. Le Bret, C. Auclair, J.d. Angelo, Structure–
activity relationships and binding mode of styrylquinolines as potent
inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture,
J. Med. Chem. 43 (2000) 1533–1540.
[21] R. Costi, R. Di Santo, M.Artico, S. Massa, R. Ragno, R. Loddo, M. La
Colla, E. Tramomtano, P. La Colla, A. Pani, 2,6-Bis(3,4,5-
trihydroxybenzylidene) derivatives of cyclohexanone: novel potent
HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-
based assays, Bioorg. Med. Chem. 12 (2004) 199–215.
[22] J.K. Buolamwini, H. Assefa, CoMFA and CoMSIA 3D QSAR and
docking studies on conformationally-restrained cinnamoyl HIV-
1 integrase inhibitors: exploration of a binding mode at the active site,
J. Med. Chem. 45 (2002) 841–852.
[7] G. Mathé, The failure of HAART to cure the HIV-1/AIDS complex.
Suggestions to add integrase inhibitors as complementary virostatics,
and to replace their continuous long combination applications by short
sequences differing by drug rotations, Biomed. Pharmacother. 55
(2001) 295–300.
[23] J.A. Estè, C. Cabrera, D. Schols, P. Cherepanov, A. Gutierrez,
M. Witrouw, C. Pannecouque, Z. Debyser, R.F. Rando, B. Clotet,
J. Desmyter, E. De Clercq, Human immunodeficiency virus glycopro-
tein gp120 as the primary target for the antiviral action of AR177
(Zintevir), Mol. Pharmacol. 53 (1998) 340–345.